Log in to search using one of your social media accounts:

 

Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
Abstract OBJECTIVE: The purpose of this case-controlled study was to determine the prevalence of anemia and incidence of perioperative blood transfusions in patients undergoing treatment for advanced ovarian cancer with neoadjuvant chemotherapy (NACT) or primary debulking surgery (PDS). METHODS: We performed a single institution review of patients diagnosed with stage IIIB-IVB epithelial ovarian cancer between 2010 and 2013 undergoing either NACT or PDS. Anemia was defined as a hemoglobin (Hgb) concentration of ≤11.5 g/dL. Continuous variables were compared by student t-test and binary variables compared...
Source: Gynecologic Oncology - May 15, 2018 Category: Cancer & Oncology Authors: O'Shea A, McCool K, Harrison R, Sampene E, Connor J, Barroilhet L Tags: Gynecol Oncol Source Type: research

Pap tests in the diagnosis of cervical cancer: Help or hinder?
Abstract OBJECTIVE: To evaluate the impact of pap tests on the time to diagnosis of cervical cancer. METHODS: In this population-based retrospective cohort study, Ontario women ≥21 years diagnosed with cervical cancer between 2011 and 2014 were identified and database data collected. The presence or absence of a pap test 0-2 years preceding cancer diagnosis was identified. Descriptive and modelling analyses were performed to determine the effect of pap results on cancer diagnosis. RESULTS: 2002 patients were identified, 75% received a pap test. 1250 patients had known cytology - 13% normal, 8% low...
Source: Gynecologic Oncology - May 15, 2018 Category: Cancer & Oncology Authors: Philp L, Jembere N, Wang L, Gao J, Maguire B, Kupets R Tags: Gynecol Oncol Source Type: research

Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.
CONCLUSIONS: In a select group of young women with stage IB1 cervical cancer, LRS compared to MRS does not appear to compromise DSS. PMID: 29776598 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 15, 2018 Category: Cancer & Oncology Authors: Tseng JH, Aloisi A, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum NR, Leitao MM Tags: Gynecol Oncol Source Type: research

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
CONCLUSIONS: Basing on the available evidence, this meta-analysis showed that high levels of ALDH1 expression correlate with worse OS and PFS in ovarian cancer patients. PMID: 29753392 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 10, 2018 Category: Cancer & Oncology Authors: Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI Tags: Gynecol Oncol Source Type: research

Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.
CONCLUSION: Our findings suggest that ILTCs are associated with adverse EC prognostic features and reduced survival in cases of early stage or serous histology. PMID: 29754740 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 10, 2018 Category: Cancer & Oncology Authors: Felix AS, Sinnott JA, Vetter MH, Rhoades J, Cohn DE, Backes FJ, Sherman ME, Suarez AA Tags: Gynecol Oncol Source Type: research

Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
This study explores the link between these variables and serum markers of ovarian cancer patients, such as signaling proteins and cytokines. METHODS: Serum samples of 39 patients with high-grade serous ovarian cancer (HGSOC) were collected at diagnosis and were retrospectively analysed for clinical characteristics, clinical parameters (NLR, CA125, platelet count) and immune profile [IL-4 (interleukin), IL-10, IL-13, IL-17, transforming growth factor-β, Arginase-1, Interferon gamma), vascular endothelial growth factor (VEGF), galectin-1 and chemokine (C-C) motif ligand 2. RESULTS: CA125 correlates negatively ...
Source: Gynecologic Oncology - May 8, 2018 Category: Cancer & Oncology Authors: Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A Tags: Gynecol Oncol Source Type: research

The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts.
CONCLUSIONS: Despite access to insurance, patients with public issued insurance had an increased risk of presenting with advanced stage cervical cancer in this cohort. These data suggest that additional barriers to screening and prevention may exist and are important for future investigation. PMID: 29751992 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 8, 2018 Category: Cancer & Oncology Authors: Davis M, Strickland K, Easter SR, Worley M, Feltmate C, Muto M, Horowitz N, Berkowitz R, Feldman S Tags: Gynecol Oncol Source Type: research

Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
Abstract OBJECTIVE: The aim of this study was to investigate the patterns of use and outcomes of adjuvant chemotherapy for patients diagnosed with FIGO stage I ovarian clear cell carcinoma (OCCC). METHODS: A cohort of patients diagnosed between 2004 and 2015 with OCCC was drawn from the National Cancer Database. Those with stage I disease who had primary surgery and underwent systematic lymphadenectomy (defined as at least 10 lymph nodes removed) were selected for further analysis. Factors associated with the administration of adjuvant chemotherapy were investigated with multivariate logistic regression. Over...
Source: Gynecologic Oncology - May 8, 2018 Category: Cancer & Oncology Authors: Nasioudis D, Mastroyannis SA, Albright BB, Haggerty AF, Ko EM, Latif NA Tags: Gynecol Oncol Source Type: research

Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage.
CONCLUSION: The Pipelle is the more cost-effective sampling strategy compared to D&C for EC diagnosis in women with PMB. From the cost-effectiveness perspective, the higher sampling failure rate of Pipelle should not be regarded as a limitation in its clinical application. PMID: 29747864 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 7, 2018 Category: Cancer & Oncology Authors: Yi Y, Bryce CL, Adambekov S, Edwards RP, Goughnour SL, Linkov F Tags: Gynecol Oncol Source Type: research

A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
CONCLUSIONS: PIPAC with cisplatin and doxorubicin may be safely used at an intraperitoneal dose of 10.5 mg/m2 and 2.1 mg/m2, respectively. Systemic toxicity of this therapy is low. PMID: 29743140 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 6, 2018 Category: Cancer & Oncology Authors: Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA Tags: Gynecol Oncol Source Type: research

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
CONCLUSIONS: Cabozantinib demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma. PMID: 29739622 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 5, 2018 Category: Cancer & Oncology Authors: Konstantinopoulos PA, Brady WE, Farley J, Armstrong A, Uyar DS, Gershenson DM Tags: Gynecol Oncol Source Type: research

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Abstract OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk in BRCA1/2 mutation carriers, but the adverse effects of the associated early-onset surgical menopause are problematic. Despite suggestive evidence, no data demonstrate whether bilateral salpingectomy alone lowers the risk of developing ovarian cancer in BRCA mutation carriers. We conducted a pilot study of bilateral salpingectomy with delayed oophorectomy (BS/DO) in BRCA mutation carriers to determine the safety and acceptability of the procedure. METHODS: In this prospective, multicenter, non-randomized pilot study, p...
Source: Gynecologic Oncology - May 4, 2018 Category: Cancer & Oncology Authors: Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH Tags: Gynecol Oncol Source Type: research

Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology.
PMID: 29729932 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 3, 2018 Category: Cancer & Oncology Authors: Naldini A, Vizzielli G, Perrone E, Gallotta V, Scambia G Tags: Gynecol Oncol Source Type: research

Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address. Sunday, March 25, 2018. By Laurel W. Rice, MD. 2017-2018 SGO president.
PMID: 29729931 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Rice LW Tags: Gynecol Oncol Source Type: research

Melanoma of the lower genital tract: Prognostic factors and treatment modalities.
Abstract Primary melanomas originating from the gynecological tract are rare and aggressive cancers. The vulva is the most frequent site (70%), followed by vagina and more rarely by cervix. The clinical outcome of patients with female genital tract melanoma is very poor, with a 5-year overall survival (OS) of 37-50% for vulvar, 13-32% for vaginal, and approximately 10% for cervical melanoma. In this systematic review, we analyzed the pathogenesis and the different factors influencing the prognosis of melanomas of the lower genital tract, with particular emphasis on biologic variables that may influence new therape...
Source: Gynecologic Oncology - May 1, 2018 Category: Cancer & Oncology Authors: Gadducci A, Carinelli S, Guerrieri ME, Aletti GD Tags: Gynecol Oncol Source Type: research

Towards identifying new therapeutic targets in cancers attributable to HPV.
PMID: 29685611 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 27, 2018 Category: Cancer & Oncology Authors: Trimble CL Tags: Gynecol Oncol Source Type: research

Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors.
Abstract OBJECTIVE: Endometrial cancer survivors are the least physically active of all cancer survivor groups and exhibit up to 70% obesity. While studies suggest lifestyle interventions result in improved health outcomes, recruitment and availability of these programs are limited. The purpose was to evaluate the acceptability and validity of the Fitbit Alta™ physical activity monitor (Fitbit) for socioculturally diverse endometrial cancer survivors. METHODS: Thirty endometrial cancer survivors were given wrist-worn Fitbits to wear for 30 days. Participants then returned the Fitbits, completed the Go...
Source: Gynecologic Oncology - April 21, 2018 Category: Cancer & Oncology Authors: Rossi A, Frechette L, Miller D, Miller E, Friel C, Van Arsdale A, Lin J, Shankar V, Kuo DYS, Nevadunsky NS Tags: Gynecol Oncol Source Type: research

Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer.
MQ Abstract OBJECTIVE: To evaluate patient-reported outcomes (PROs) between women treated by laparoscopic, robotic and open approaches for endometrial cancer. METHODS: Prospective cohort study comparing PRO at baseline, short- (1 and 3 weeks) and long-term (12 and 24 weeks) follow-up postoperatively. Quality of life (QOL) measures were the Functional Assessment of Cancer Therapy (FACT-G), EuroQol Five Dimensions (EQ-5D), and Brief Pain Inventory (BPI). Sexual health measures were the Female Sexual Function Index (FSFI) and the Sexual Adjustment and Body Image Scale for Gynecologic Cancer (SABIS-G). ...
Source: Gynecologic Oncology - April 19, 2018 Category: Cancer & Oncology Authors: Ferguson SE, Panzarella T, Lau S, Gien LT, Samouëlian V, Giede C, Steed H, Le T, Renkosinski B, Bernardini MQ Tags: Gynecol Oncol Source Type: research

The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
Abstract OBJECTIVES: The baseline phase of the Onclarity trial was conducted to determine the screening performance of the Onclarity human papillomavirus (HPV) assay for detecting cervical cancer and precancer (≥CIN2) during triage of women ≥21 years with ASC-US cytology, as an adjunct test in women ≥30 years with normal cytology and for primary screening (HPV alone) in women ≥25 years. METHODS: 33,858 women ≥21 years were enrolled during routine clinic visits. All women with abnormal cytology, women ≥25 years that were high-risk HPV positive, and a random subset of women ≥25 ...
Source: Gynecologic Oncology - April 19, 2018 Category: Cancer & Oncology Authors: Stoler MH, Wright TC, Parvu V, Vaughan L, Yanson K, Eckert K, Karchmer T, Kodsi S, Cooper CK Tags: Gynecol Oncol Source Type: research

Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
CONCLUSIONS: The HerSwab™ had good agreement with physician sampling in detecting HPV, and adequate performance in detecting high-grade lesions among women referred to colposcopy for abnormal cytology. PMID: 29678360 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 17, 2018 Category: Cancer & Oncology Authors: El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb W, Hemmings R, Behr MA, Franco EL, CASSIS Study Group, Liang V, Martins C, Duarte S, Sarban N, Geddes P, Massa A, Samios K, Aboufadl S, Verdon S, Pereria C, Lacroix I Tags: Gynecol Oncol Source Type: research

Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
CONCLUSIONS: In screening for LS in EC, IHC for MMRPs can be performed with identical accuracy on either EMB/C or hysterectomy specimens. Routine testing of diagnostic EMB/Cs may lead to earlier detection of MMRP deficiency, with improved patient uptake of genetic counseling and potential for earlier identification of immunotherapy candidates. Furthermore, reliable IHC-based LS screening performed on EMB/C can guide patient management and genetic counseling in patients unable to undergo hysterectomy. PMID: 29656794 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Chapel DB, Yamada SD, Cowan M, Lastra RR Tags: Gynecol Oncol Source Type: research

Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation.
CONCLUSIONS: ERAS program implementation resulted in reductions in narcotic requirements and PCA use without changes in length of stay or readmission rates. Compliance should be diligently audited during the implementation phase of ERAS programs, with special attention to adherence to pre-existing core safety measures. PMID: 29661495 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Bergstrom JE, Scott ME, Alimi Y, Yen TT, Hobson D, Machado KK, Tanner EJ, Fader AN, Temkin SM, Wethington S, Levinson K, Sokolinsky S, Lau B, Stone RL Tags: Gynecol Oncol Source Type: research

Abuse, cancer and sexual dysfunction in women: A potentially vicious cycle.
Abstract More than 30% of women have a history of abuse. Women with cancer may be at substantially increased risk for abuse, but this issue is rarely discussed in the course of oncology care. Women with a history of abuse who present for cancer care commonly have a high prevalence of co-morbid illness. Sexual dysfunction, a highly prevalent but under-recognized condition among women of all ages, is also more common among both women with a history of abuse and women with cancer. Although common after cancer, sexual dysfunction, like abuse, can be stigmatizing and often goes undiagnosed and untreated. This review fi...
Source: Gynecologic Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Lees BF, Stewart TP, Rash JK, Baron SR, Lindau ST, Kushner DM Tags: Gynecol Oncol Source Type: research

Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
CONCLUSION: Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer. PMID: 29661497 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T Tags: Gynecol Oncol Source Type: research

Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
CONCLUSIONS: Low cost interventions that target education of both providers and patients regarding the importance of genetic testing along with utilization of the EHR and streamlined patient appointment services can significantly increase rates of genetic testing completion. PMID: 29653687 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL Tags: Gynecol Oncol Source Type: research

Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients.
Abstract BACKGROUND: To re-evaluate the efficacy of the prognostic factors currently employed in the treatment of malignant gestational trophoblastic neoplasia. METHODS: Clinical data from the Gestational Trophoblastic Disease (GTD) Center at Peking Union Medical Hospital (PUMCH) collected between January 2002 and December 2013 were retrospectively analyzed. Univariate and multivariate analyses of prognostic factors were performed using the Cox proportional hazards model. A new hazard ratio (HR)-based prognostic scoring scale was established and compared with the original scoring system. RESULTS: In tota...
Source: Gynecologic Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Jiang F, Wan XR, Xu T, Feng FZ, Ren T, Yang JJ, Zhao J, Yang T, Xiang Y Tags: Gynecol Oncol Source Type: research

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
Abstract Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy. If VEGFR-TKIs are licensed for use in ovarian cancer, patients will require prompt and effective management of adverse events, including diarrhea, to optimize compliance and benefit. As diarrhea is one of the most prevalent toxiciti...
Source: Gynecologic Oncology - April 4, 2018 Category: Cancer & Oncology Authors: Liu J, Nicum S, Reichardt P, Croitoru K, Illek B, Schmidinger M, Rogers C, Whalen C, Jayson GC Tags: Gynecol Oncol Source Type: research

Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.
CONCLUSIONS: Despite a decrease in physical functioning, persistent low body image and sexual pleasure, most women were satisfied with their decision and would undergo pelvic exenteration again. This study identifies survivorship issues that should be addressed after PE. PMID: 29622276 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 2, 2018 Category: Cancer & Oncology Authors: Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT Tags: Gynecol Oncol Source Type: research

Towards the elimination of health care disparities in gynecologic oncology: Call to action.
PMID: 29605042 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Del Carmen MG, Rice LW Tags: Gynecol Oncol Source Type: research

An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students.
CONCLUSIONS: Primary prevention and early detection are key interventions for reducing disparities in cervical cancer incidence and treatment. Community outreach efforts play an important role in reducing inequities in cancer among high-risk groups. The educational intervention utilized in this study was successful in improving knowledge about HPV and cervical cancer. PMID: 29605043 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Staples JN, Wong MS, Rimel BJ Tags: Gynecol Oncol Source Type: research

Racial disparities in molecular subtypes of endometrial cancer.
Abstract OBJECTIVES: Racial differences in the molecular subtypes of endometrial cancer and associations with progression-free survival (PFS) were evaluated. METHODS: Molecular, clinical and PFS data were acquired from the Cancer Genome Atlas (TCGA) including classification into the integrative, somatic copy number alteration and transcript-based subtypes. The prevalence and prognostic value of the aggressive molecular subtypes (copy number variant [CNV]-high, cluster 4 or mitotic) were evaluated in Black and White patients. RESULTS: There were 337 patients including 14% self-designated as Black, 27% wit...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Dubil EA, Tian C, Wang G, Tarney CM, Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM Tags: Gynecol Oncol Source Type: research

Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer.
Abstract OBJECTIVES: Black race has been associated with increased 30-day morbidity and mortality following surgery for endometrial cancer. Black women are also less likely to undergo laparoscopy when compared to white women. With the development of improved laparoscopic techniques and equipment, including the robotic platform, we sought to evaluate whether there has been a change in surgical approach for black women, and in turn, improvement in perioperative outcomes. METHODS: Using the American College of Surgeons' National Surgical Quality Improvement Project's database, patients who underwent hysterectomy...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Lee J, Gerber D, Aphinyanaphongs Y, Curtin JP, Boyd LR Tags: Gynecol Oncol Source Type: research

Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
This study sought to examine treatment-related toxicities and outcomes of older versus younger patients participating in phase 1 clinical trials. METHODS: A retrospective analysis of patients enrolled in phase 1 clinical trials for gynecologic malignancies from 2010 to 2016 was performed. Demographic and clinic-pathologic data was abstracted. Toxicities were defined as either grade III or IV by CTCAE criteria. Best response was calculated using RECIST criteria. Associations between categorical variables were determined using Fisher's exact test and continuous variables using Wilcoxon rank sum test. Survival was estima...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC Tags: Gynecol Oncol Source Type: research

Biological origins of sexual orientation and gender identity: Impact on health.
Abstract Gynecologic Oncologists are sometimes consulted to care for patients who present with diverse gender identities or sexual orientations. Clinicians can create more helpful relationships with their patients if they understand the etiologies of these diverse expressions of sexual humanity. Multidisciplinary evidence reveals that a sexually dimorphic spectrum of somatic and neurologic anatomy, traits and abilities, including sexual orientation and gender identity, are conferred together during the first half of pregnancy due to genetics, epigenetics and the diversity of timing and function of sex chromosomes,...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: O'Hanlan KA, Gordon JC, Sullivan MW Tags: Gynecol Oncol Source Type: research

Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.
CONCLUSION: Significant racial disparities persist in the delivery of evidence-based care. Black women with ovarian, endometrial, and cervical cancer continue to experience higher cancer-specific mortality than other groups. PMID: 29605048 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Rauh-Hain JA, Melamed A, Schaps D, Bregar AJ, Spencer R, Schorge JO, Rice LW, Del Carmen MG Tags: Gynecol Oncol Source Type: research

Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
CONCLUSION: Statistically significant socio-demographic disparities in PDS and survival outcomes were not observed among women with advanced OC treated at this HVC. Increased efforts are needed to centralize care to and increase the diversity of pts treated at HVCs. PMID: 29605049 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, Long Roche KC, Brown CL Tags: Gynecol Oncol Source Type: research

Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
Abstract BACKGROUND: Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if, at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (CCC) serving a diverse racial and socioeconomic population, race is independently associated with differences in survival. METHODS: A retrospective review of women with EOC diagnosed between 2004-2009 undergoing treatment with follow-up at our institution was performed. Records were reviewed for demographics, comorbidities (...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Dilley S, Erickson BK, Phillips CE, Kennemer CR, Zhang B, Matin T, Martin JY, Shah MS, Michael Straughn J, Leath CA Tags: Gynecol Oncol Source Type: research

Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
CONCLUSIONS: Delays in starting RT/CRT for cervical cancer increased from 2004 to 2014. Delays disproportionately affect NHB and Hispanic women. However, increased TTI was not associated with increased mortality for women receiving CRT. Further study of TTI's impact on other endpoints is warranted to determine if TTI represents an important quality indicator. PMID: 29605051 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Ramey SJ, Asher D, Kwon D, Ahmed AA, Wolfson AH, Yechieli R, Portelance L Tags: Gynecol Oncol Source Type: research

The impact of nativity on cervical cancer survival in the public hospital system of Queens, New York.
Abstract OBJECTIVE: We studied cervical cancer patients who presented to the Public Hospital System in ethnically-diverse Queens, New York from 2000 to 2010 with the purpose of examining the relationship between nativity (birthplace) and survival. METHODS: A retrospective review of tumor registries was used to identify patients diagnosed with cervical cancer between January 1, 2000 and December 31, 2010. Using electronic medical records, data from 317 patients were available for this analysis. RESULTS: The majority of patients were born outside the United States (US) (85.5% versus 14.5%). One hundred pat...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Hagopian GS, Lieber M, Dottino PR, Margaret Kemeny M, Li X, Overbey J, Clark LD, Beddoe AM Tags: Gynecol Oncol Source Type: research

A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.
This article will update the framework of disparities to incorporate a broader understanding of the social determinants of health and how they affect health equity by addressing the root causes of disparities within the health care system. Special populations are identified who are at risk for health inequities which include but are not limited to Black race, underserved racial and ethnic minorities (e.g. indigenous peoples, low English fluency), trans/gender nonconforming people and rural populations. Each of these populations at risk have unique structural barriers within the healthcare system impacting gynecologic cance...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Temkin SM, Rimel BJ, Bruegl AS, Gunderson CC, Beavis AL, Doll KM Tags: Gynecol Oncol Source Type: research

Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications.
Abstract Within gynecologic oncology are two of the top five widest Black-White mortality gaps among all cancer diagnoses in the United States. A rich body of work from the social sciences, including anthropology, sociology and social epidemiology, have broadened the understanding of and research approaches to the study of health and healthcare inequity experienced by Black Americans. Yet, these intellectual advancements in understanding are virtually absent from the gynecologic oncology literature. The goal of this analytic essay will be to introduce three current frameworks of studying racial inequity: The Ecoso...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Doll KM Tags: Gynecol Oncol Source Type: research

Disparities in genetics assessment for women with ovarian cancer: Can we do better?
Abstract OBJECTIVE: We sought to characterize referral patterns for genetic counseling for women with ovarian cancer and hypothesized that differences in referral and testing rates are shaped by socioeconomic factors. METHODS: Patients were identified by pathology reports from August 2012 to January 2016 containing the words "serous" or "ovarian." Patient information was obtained via electronic medical record. Primary outcomes were placement of a genetics referral and completion of counseling. A secondary outcome was completion of genetic testing. RESULTS: We identified 246 women with...
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM Tags: Gynecol Oncol Source Type: research

Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.
CONCLUSIONS: Navigation services for AI cervical cancer patients did not alter initiation or completion of treatment. Navigation programs may provide less tangible benefits to AI cervical cancer patients and further study is warranted. PMID: 29605056 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Dockery LE, Motwani A, Ding K, Doescher M, Dvorak JD, Moore KN, Holman LL Tags: Gynecol Oncol Source Type: research

First nations people's perspectives on barriers and supports for enhancing HPV vaccination: Foundations for sustainable, community-driven strategies.
CONCLUSIONS AND FUTURE DIRECTION: Ongoing dialogue and co-development of community-based strategies to increase HPV vaccine uptake are required. The identification of possible barriers to HPV vaccination in a Canadian Indigenous population contributes to limited global literature on this subject and may inform researchers and policy makers who work with Indigenous populations in other regions. PMID: 29605057 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Henderson RI, Shea-Budgell M, Healy C, Letendre A, Bill L, Healy B, Bednarczyk RA, Mrklas K, Barnabe C, Guichon J, Bedingfield N, MacDonald S, Colquhoun A, Glaze S, Nash T, Bell C, Kellner J, Richardson R, Dixon T, Starlight J, Runner G, Nelson G Tags: Gynecol Oncol Source Type: research

Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
Abstract BACKGROUND: Transcription factor activator protein-2β (TFAP-2β) was previously reported to constituted promoter activity in endometrial carcinoma (EC). We evaluated the role of TFAP2B in ECs using publicly available data from The Cancer Genome Atlas (TCGA). METHODS: The relationship between clinical pathologic features and TFAP2B were analyzed with the Wilcoxon signed-rank test and logistic regression. Clinicopathologic characteristics associated with overall survival in TCGA patients using Cox regression and the Kaplan-Meier method. Gene Set Enrichment Analysis (GSEA) was performed using T...
Source: Gynecologic Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Wu H, Zhang J Tags: Gynecol Oncol Source Type: research

Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
CONCLUSIONS: Among chemotherapy-treated ovarian cancer patients, SPN levels were stable over time. In contrast, MPN symptoms significantly improved at 12months. These symptoms seriously impacted HRQoL. Future studies should examine the impact of different treatment decisions and alterations on CIPN, so recommendations can be made to reduce CIPN (prevalence). PMID: 29605500 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Bonhof CS, Mols F, Vos MC, Pijnenborg JMA, Boll D, Vreugdenhil G, Ezendam NPM, van de Poll-Franse LV Tags: Gynecol Oncol Source Type: research

Women treated for gynaecological cancer during young adulthood - A mixed-methods study of perceived psychological distress and experiences of support from health care following end-of-treatment.
CONCLUSION: Results identify the importance of support and longer-term follow-up for young survivors of gynaecological cancer. The support needs to be organised to meet this group's specific needs. PMID: 29588102 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 24, 2018 Category: Cancer & Oncology Authors: Mattsson E, Einhorn K, Ljungman L, Sundström-Poromaa I, Stålberg K, Wikman A Tags: Gynecol Oncol Source Type: research

Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.
Abstract OBJECTIVE: The cervical cancer disparity continues to exist and has widened between Black and non-Hispanic White women. Human Papillomavirus (HPV) vaccines could potentially reduce this disparity, yet remain underused among Black female adolescents. We investigated psychosocial and cultural factors associated with Black mothers' intentions to vaccinate their daughters against HPV, and explored views toward a HPV vaccine mandate. METHODS: In this quantitative dominant, mixed methods study, cross sectional surveys (n=237) and follow-up semi-structured interviews (n=9) were conducted with Black mothers ...
Source: Gynecologic Oncology - March 24, 2018 Category: Cancer & Oncology Authors: Cunningham-Erves J, Forbes L, Ivankova N, Mayo-Gamble T, Kelly-Taylor K, Deakings J Tags: Gynecol Oncol Source Type: research

Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
PMID: 29573822 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 21, 2018 Category: Cancer & Oncology Authors: Matsuoka A, Tate S, Nishikimi K, Shozu M Tags: Gynecol Oncol Source Type: research

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
CONCLUSION: The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. Additional validation studies using the biomarker combination in ovarian cancer patients are warranted. PMID: 29572027 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 20, 2018 Category: Cancer & Oncology Authors: Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Tags: Gynecol Oncol Source Type: research